Belgian biotech targets SIK3 to shift autoimmune care from blunt suppression to proactive, systemic inflammatory control.
Following a rebrand from Onco3R Therapeutics, Coultreon Biopharma has closed an oversubscribed $125 million Series A financing round. It’s a significant capital injection, led by Sofinnova Investments with co-leads Forbion and Novo Holdings, and it signals a focused pivot from the company’s former identity as Onco3R Therapeutics.
The objective? To push their lead asset, COL-5671, through Phase 1 and into mid-stage clinical trials for psoriasis and ulcerative colitis, with an eye toward proof-of-concept by 2027.
Longevity.Technology: Coultreon’s $125 million Series A is, on one level, another confident bet on immunology; more interestingly, it is a bet on whether inflammatory control can become less blunt instrument and more biological re-tuning. SIK3 inhibition is still early, and autoimmune drug development is littered with elegant mechanisms that failed to survive contact with Phase 2 reality – biotech’s own version of “seemed like a good idea at the time” – but an oral, once-daily therapy that can suppress TNFα and IL-23 while increasing IL-10 has the makings of a compelling healthspan story, not merely a psoriasis or ulcerative colitis story.
Chronic immune dysregulation is one of the quiet vandals of aging biology; if Coultreon can show durable efficacy without simply swapping inflammation for immunosuppression, COL-5671 could sit neatly in the emerging category of medicines that treat disease today while nudging medicine toward prevention, resilience and longer-lived function tomorrow.
Targeting immune balance
At the center of this thesis is SIK3, part of a kinase family implicated in regulating inflammatory gene transcription. By inhibiting SIK3, COL-5671 reduces the production of pro-inflammatory cytokines like TNFα and IL-23, while simultaneously bumping up the expression of the immunoregulatory cytokine IL-10. It’s a push for balance over blockage – a distinction that matters when you’re looking at chronic settings.
Bridging the clinical gap
The molecule itself is designed for once-daily oral dosing, which, in a market often dominated by costly, injectable biologics, carries both clinical and practical weight. Early data suggests favorable pharmacokinetics and sustained cytokine suppression, though as we know, the transition from successful preclinical models to Phase 2 reality is the graveyard of many otherwise brilliant ideas. Yet, the safety profile, backed by extensive toxicology, has provided enough confidence for a syndicate that includes heavyweights like Regeneron Ventures, Balyasny Asset Management and Galapagos – the latter of whom originally developed the molecule before transferring ownership to Coultreon last year. The full syndicate also includes Luma Group, Samsara BioCapital, Longwood Fund and Finchley Healthcare Ventures.
“This financing marks a major inflection point for our company,” says CEO Pierre Raboisson. “With the support of this top-tier syndicate, we are well positioned to advance our SIK program, while unlocking the broader potential of our pipeline. I am extremely proud of what the team has achieved, and I look forward to advancing our novel first-in-class therapies to patients.”
The oncology-immunology crossover
The pivot from oncology to immunology feels like a symptom of a broader industry trend. We are seeing pathways previously scrutinized for their role in cancer redeployed to manage the chronic, low-grade dysregulation that defines much of human aging. Investors seem to agree. The fact that this round was oversubscribed in a notoriously selective funding environment says as much about the appetite for SIK-targeting platforms as it does about the team.
“We are impressed by Coultreon’s scientific depth, disciplined development strategy, and the strength of its team,” says Maha Katabi, General Partner at Sofinnova Investments. “We have strong conviction in the company’s lead SIK3 program to be valuable across a range of auto-immune diseases where patients would benefit from an alternative oral treatment option.”
A shift in systemic care
Whether SIK3 inhibition can deliver on the promise of durable, broad-spectrum control remains the fundamental question. The early signals are compelling, but we’ve learned enough to know that human biology rarely adheres to the neat linear models we build in silico. Regardless, the trajectory is unmistakable. We are moving toward a future where, rather than waiting for an acute pathology to manifest, we look to modulate the system’s underlying inflammatory tone. If SIK3 inhibition can successfully dampen the chronic, low-grade inflammation that characterizes inflammaging, Coultreon might be looking at a tool that transcends traditional auto-immune indications – offering a path toward maintaining functional resilience well into later life.
Some advances arrive with fanfare; others, like this one, may just quietly recalibrate the system.
